Denali Therapeutics (DNLI) Receivables - Other (2017 - 2022)
Denali Therapeutics (DNLI) posted quarterly Receivables - Other of $357000.0 for Q2 2022, down 77.22% year-over-year from $1.6 million in Q2 2021, and down 70.88% quarter-over-quarter from $1.2 million in Q4 2021.
Denali Therapeutics (DNLI) Receivables - Other (2017 - 2022) Analysis & Trends
Denali Therapeutics (DNLI) has reported Receivables - Other for 5 consecutive years, with $357000.0 the latest figure, recorded in Q2 2022.
- In Q2 2022, Receivables - Other fell 77.22% year-over-year to $357000.0; the TTM figure through Jun 2022 stood at $357000.0 (down 77.22% YoY), while the FY2021 annual figure was $1.2 million, down 78.39% from the prior year.
- Receivables - Other eased to $357000.0 in Q2 2022 per DNLI's latest filing, from $1.2 million in the prior quarter.
- Across five years, Receivables - Other topped out at $5.7 million in Q4 2020 and bottomed at $357000.0 in Q2 2022.
- Historically, Receivables - Other has averaged $2.0 million across 4 years, with a median of $1.2 million in 2021.
- Annual changes were most pronounced in 2018 — Receivables - Other jumped 154.74% — and 2021, when it plunged 78.39%.
- Denali Therapeutics' Receivables - Other stood at $1.2 million in 2018, then surged by 380.03% to $5.7 million in 2020, then slumped by 78.39% to $1.2 million in 2021, then sank by 70.88% to $357000.0 in 2022.
- Business Quant data shows DNLI's Receivables - Other at $357000.0 in Q2 2022, $1.2 million in Q4 2021, and $1.2 million in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Denali Therapeutics | 3.90 Bn | 3.90 Bn | 3.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 357,000.00 |
| Jun 30, 2022 | 357,000.00 |
| Dec 31, 2021 | 1.23 Mn |
| Dec 31, 2021 | 1.23 Mn |
| Sep 30, 2021 | 1.19 Mn |
| Sep 30, 2021 | 1.19 Mn |
| Jun 30, 2021 | 1.57 Mn |
| Jun 30, 2021 | 1.57 Mn |
| Mar 31, 2021 | 2.51 Mn |
| Mar 31, 2021 | 2.51 Mn |
| Dec 31, 2020 | 5.67 Mn |
| Dec 31, 2020 | 5.67 Mn |
| Dec 31, 2018 | 1.18 Mn |
| Dec 31, 2018 | 1.18 Mn |
| Dec 31, 2017 | 464,000.00 |
| Dec 31, 2017 | 464,000.00 |